Leju Holdings Ltd Finance and Economics Wang MinOn November 8th, Shanghai Ying Nuowei Medical device Co., Ltd. (hereinafter referred to as "Ying Nuowei") submitted the form to the main board of the Hong Kong Stock Exchange, Goldman Sachs Group and China International Capital Corporation.As a co-sponsor. Previously, Invid handed in the watch on April 29, 2022.

According to the prospectus, Invid is China's leading provider of integrated solutions for non-vascular interventional surgery, with operations all over the world. So far, the company has 33 approved products in China, the United States, Europe and ╱ or Japan and 16 products under development.

In terms of performance, for the six months ended June 30, 2020, 2021 and 2022, Invid's income was about 137 million yuan, 255 million yuan and 97.769 million yuan respectively; gross profit was 86.832 million yuan, 163 million yuan and 56.265 million yuan; gross profit margin was 63.2%, 63.7% and 57.5%, respectively.

Before the listing, Invid completed six rounds of financing, the most recent of which was the C2 round at the end of 2021. According to the prospectus, Yingnowei has completed 110 million yuan A1 round, 30 million yuan A2 round, 30 million yuan B1 round, 30 million yuan B2 round, 437.5 million yuan C1 round and 250 million yuan C2 round financing, totaling about 887.5 million yuan.

According to the prospectus, Invid is valued at 591 million yuan, 611 million yuan, 715 million yuan, 1.03 billion yuan, 2.8 billion yuan and 6.25 billion yuan respectively after A1, A2, B1, C1 and C2 rounds of financing. Among them, the company's valuation began to soar after the C-Series financing.

Specifically, Invid's valuation increased from 591 million yuan to 6.25 billion yuan between 2019 and 2021, a relative increase of 9.6 times. At the same time, Invid's cost per share increased from 24.67 yuan in January 2019 to 140.0 yuan in October 2021, a relative increase of 4.7 times.

Responsible Editor: Zhang Haiying